Breaking Finance News

A statement released earlier today by H.C. Wainwright about Inotek Pharmaceuticals (NASDAQ:ITEK) bumps the target price to $22.00

Boasting a price of $8.47, Inotek Pharmaceuticals (NASDAQ:ITEK) traded 1.93% higher on the day. The last stock close is up 4.50% from the two hundred day average, compared with the S&P 500 which has fallen -0.01% over the same time period. ITEK has registered a 50-day moving average of $7.08 and two hundred day average of $8.10. 282,957 shares of ITEK were exchanged, up from ann avg. trading volume of 273,931

Inotek Pharmaceuticals (NASDAQ:ITEK) had its estimated target price raised to $22 by H.C. Wainwright in an issued report released 9/20/2016. The latest target price indicates a possible upside of 1.60% based on the company’s most recent closing price.

Previously on 7/27/2015, Canaccord Genuity released a statement about Inotek Pharmaceuticals(NASDAQ:ITEK) upped the target price from $11.00 to $30.00 that indicated a possible upside of 0.70%.

Recent Performance Graphic:

Inotek Pharmaceuticals (NASDAQ:ITEK)

Inotek Pharmaceuticals has a one-year low of $5.81 and a one-year high of $14.07 . ITEK’s total market value is presently $0.0.

General Information About Inotek Pharmaceuticals (NASDAQ:ITEK)

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), and of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.